[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352459-105":59,"doc-detail-352459-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","reprogramming-tumor-immunity-through-apobec3s-mediated-mutagenesis-from-genome-instability-to-immune-checkpoint-interactions","Reprogramming tumor immunity through APOBEC3s-mediated mutagenesis - from genome instability to immune checkpoint interactions","","Review of APOBEC3s identifies them as endogenous cytidine deaminases that generate mutation patterns associated with genomic instability, clonal evolution, and therapy adaptation. Beyond driving tumor evolution, APOBEC3 activity alters antitumor immunity by increasing mutational burden and producing neoantigens that may enhance CD8+ T-cell infiltration and interferon signaling. The review also addresses immunosuppressive ambivalence, where sustained APOBEC activation can reinforce chronic inflammation and PD-1/PD-L1–interferon signaling, promoting T-cell dysfunction, immune escape, and resistance to checkpoint blockade. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/reprogramming-tumor-immunity-through-apobec3s-mediated-mutagenesis-from-genome-instability-to-immune-checkpoint-interactions/352459/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/reprogramming-tumor-immunity-through-apobec3s-mediated-mutagenesis-from-genome-instability-to-immune-checkpoint-interactions/352459.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are APOBEC3s and what roles do they play in cancers?","Question",{"text":112,"@type":113},"APOBEC3s are cytidine deaminases that can generate characteristic somatic mutations. In cancer, their activity contributes to genomic instability and increases tumor mutational burden, which can shape immune responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How can APOBEC3-mediated mutations enhance antitumor immunity?",{"text":117,"@type":113},"APOBEC3-induced mutations can raise mutational burden and create neoantigens, potentially improving CD8+ T-cell infiltration and interferon signaling.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is there debate about inhibiting or modulating APOBEC3s for therapy?",{"text":121,"@type":113},"The review highlights functional ambivalence: sustained APOBEC activation may also promote immunosuppressive circuits, such as chronic inflammation and PD-1/PD-L1–interferon signaling, leading to T-cell dysfunction and resistance to immune checkpoint blockade.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352459,1790192975,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","TYPE Review  \nPUBLISHED 11 February 2026  \nDOI 10.3389/fimmu.2026.1765368  \nOPEN ACCESS  \nEDITED BY  \nFan Yang,  \nThe University of Chicago, United States  \nREVIEWED BY  \nJiaqi Zhao,  \nThe University of Chicago, United States Jiacheng Li,  \nUniversity of Chicago Medicine, United States  \n*CORRESPONDENCE  \nYang Yang  \n[yangyang1985_2012@163.com](yangyang1985_2012@163.com)[ ](yangyang1985_2012@163.com)Hao Guo  \n[guohao@cmu.edu.cn](guohao@cmu.edu.cn)[ ](guohao@cmu.edu.cn)†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 11 December 2025  \nREVISED 08 January 2026  \nACCEPTED 26 January 2026  \nPUBLISHED 11 February 2026  \nCITATION  \nLi Q, Wan W, Zhu Z, Lin X, Wang F, Li M, Guo H and Yang Y (2026)  \nReprogramming tumor immunity through APOBEC3s-mediated mutagenesis: from genome instability to immune checkpoint interactions. Front. Immunol. 17:1765368 .  \ndoi: 10.3389/fimmu.2026.1765368  \nCOPYRIGHT  \n© 2026 Li, Wan, Zhu, Lin, Wang, Li, Guo and Yang. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nReprogramming tumor immunity through APOBEC3s-mediated mutagenesis: from genome instability to immune checkpoint interactions  \nQiaoxi Li 1,2†, Wenyu Wan 1,2†, Zihan Zhu 1,2, Xuanduo Lin 1,2, Fei Wang 1,2, Mengmeng Li 1,2, Hao Guo 1,2* and Yang Yang 1,2*  \n1 Department of Dermatology, The First Hospital of China Medical University, Shenyang, China, 2 Key Laboratory of Immunodermatology, Ministry of Education, and National Health Commission, National Joint Engineering Research Center for Theranostics of Immunological Skin Diseases, Shenyang, China  \nThe apolipoprotein B mRNA editing catalytic polypeptide-like (APOBEC) family was ﬁrst deﬁned as an innate antiviral defense system, but the APOBEC3 subfamily (APOBEC3s) is now recognized as a major endogenous source of somatic mutagenesis in cancer . APOBEC3s enzymes, particularly APOBEC3A and APOBEC3B, generate characteristic mutation patterns that promote genomic instability, clonal evolution, and adaptation to therapy. Beyond driving tumor evolution, APOBEC3 activity reshapes antitumor immunity in solid cancers. APOBEC3-induced mutations increase tumor mutational burden and create neoantigens that can enhance CD8+ T-cell inﬁltration and interferon signaling. However, sustained APOBEC activation may also reinforce immunosuppressive circuits: through chronic inﬂammation and PD-1/PD-L1–interferon signaling, tumors can induce T-cell dysfunction, immune escape, and resistance to immune checkpoint blockade. This functional ambivalence has sparked debate over whether APOBEC3s should be inhibited to limit genomic instability, leveraged to enhance tumor immunogenicity, or modulated dynamically in a context-dependent manner. This review outlines the immune landscape and biochemical characteristics of the APOBEC3 family and situates these features within broader cancer-related disease contexts. APOBEC3-mediated mutagenesis is discussed as a mechanistic link between genomic instability and tumor–immune crosstalk in solid tumors, with emphasis on its relationships to immunoediting, immune checkpoint pathways, and therapeutic responses. Context-dependent associations of APOBEC3 activity with immune activation or immune evasion are also considered, together with their implications for strategies that modulate this pathway.  \nKEYWORDS  \nAPOBEC3 cytidine deaminases, genomic instability and DNA repair, immune checkpoint blockade, mutational signatures, neoantigens and immunotherapy resistance, precision immuno-oncology, tumor immune microenvironment, tumor immunoediting  \nFro","cbCaiaLY73RIUBSL","https://ap.wps.com/l/cbCaiaLY73RIUBSL","pdf",4242427,15,"English","# Introduction\n## APOBEC family and enzymatic roles\n## APOBEC3s as a link between mutagenesis and immunity\n## Ambivalent effects on tumor immunity\n# Immune checkpoint interactions and therapeutic responses\n## Mechanistic links: genomic instability to tumor–immune crosstalk\n## Context-dependent immune activation versus immune evasion","[{\"question\":\"What are APOBEC3s and what roles do they play in cancers?\",\"answer\":\"APOBEC3s are cytidine deaminases that can generate characteristic somatic mutations. In cancer, their activity contributes to genomic instability and increases tumor mutational burden, which can shape immune responses.\"},{\"question\":\"How can APOBEC3-mediated mutations enhance antitumor immunity?\",\"answer\":\"APOBEC3-induced mutations can raise mutational burden and create neoantigens, potentially improving CD8+ T-cell infiltration and interferon signaling.\"},{\"question\":\"Why is there debate about inhibiting or modulating APOBEC3s for therapy?\",\"answer\":\"The review highlights functional ambivalence: sustained APOBEC activation may also promote immunosuppressive circuits, such as chronic inflammation and PD-1/PD-L1–interferon signaling, leading to T-cell dysfunction and resistance to immune checkpoint blockade.\"}]","Reprogramming tumor immunity through APOBEC3s-mediated mutagenesis - from genome instability to immune checkpoint interactions | PDF",1790099779,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81298c27b6495e4cc349189c232a7c45.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38f3944d25db52bdda215d5cf35f77cb.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c27c45f631e886353b7082447cdc55ed.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/caefa9018ad49599a6c06e1dacf5d9d8.webp",980,1385]